What is NDC 82293-030?

82293-030 is the product NDC for everolimus, Everolimus 2.5 mg/1 tablet, listed with the FDA by Novugen Pharma (USA) LLC.. It has 3 package NDCs, shown above in 10- and 11-digit form.

Novugen Pharma (USA) LLC., NDC labeler code 82293. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for everolimus?

65 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

everolimus NDC 82293-030 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)82293-030Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82293-0030Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
82293-030-10	8229300301082293003010	28 TABLET in 1 BOTTLE (82293-030-10)Marketed from Mar 30, 2026
82293-030-21	8229300302182293003021	4 BLISTER PACK in 1 CARTON (82293-030-21) / 7 TABLET in 1 BLISTER PACK (82293-030-20)Marketed from Mar 30, 2026
82293-030-31	8229300303182293003031	1 POUCH in 1 CARTON (82293-030-31) / 3 BLISTER PACK in 1 POUCH / 10 TABLET in 1 BLISTER PACK (82293-030-30)Marketed from Mar 30, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): everolimus
Generic name (nonproprietary): everolimus
Active ingredients: Everolimus — 2.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Novugen Pharma (USA) LLC.NDC labeler code 82293
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219955
Marketing start: Mar 30, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Immunologic Activity (Physiologic effect)Protein Kinase Inhibitors (Mechanism)mTOR Inhibitors (Mechanism)
Identifiers: Product ID 82293-030_4ca7b927-0d89-0be6-e063-6394a90af200SPL ID 4ca7b927-0d89-0be6-e063-6394a90af200SPL set ID 67e62e26-448d-46ec-b5a1-00dc1b5e26c6RxCUI 845507, 845515, 998189, 1119400UNII 9HW64Q8G6G
Pharmacologic class: Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N482293003010 followed by a unit qualifier and the quantity

Package 82293-0030-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 10, 2026.

Indications (excerpt from the label)

Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tab…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 82293-030

What is NDC 82293-030?: 82293-030 is the product NDC for everolimus, Everolimus 2.5 mg/1 tablet, listed with the FDA by Novugen Pharma (USA) LLC.. It has 3 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: everolimus.
What is the active ingredient?: Everolimus.
Who is the labeler?: Novugen Pharma (USA) LLC., NDC labeler code 82293. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for everolimus?: 65 other product NDCs are listed under this name. See all everolimus NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other everolimus NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Everolimus	Everolimus .25 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-003	72319-0003-0272319-0003-60
Everolimus	Everolimus .5 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-015	72319-0015-0272319-0015-60
Everolimus	Everolimus .75 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-016	72319-0016-0272319-0016-60
Everolimus	Everolimus 1 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-017	72319-0017-0272319-0017-60
everolimus	Everolimus 7.5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-032	82293-0032-1082293-0032-2182293-0032-31
everolimus	Everolimus 5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-031	82293-0031-1082293-0031-2182293-0031-31
everolimus	Everolimus 10 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-033	82293-0033-1082293-0033-2182293-0033-31
everolimus	Everolimus .75 mg/1	TabletOral	Aurobindo Pharma Limited	59651-933	59651-0933-60
everolimus	Everolimus .25 mg/1	TabletOral	Aurobindo Pharma Limited	59651-931	59651-0931-60
everolimus	Everolimus .5 mg/1	TabletOral	Aurobindo Pharma Limited	59651-932	59651-0932-60

All 66 everolimus NDCs

Other NDCs under ANDA 219955

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219955
Product	Strength	Form · route	Labeler	Product NDC
everolimus	Everolimus 5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-031
everolimus	Everolimus 7.5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-032
everolimus	Everolimus 10 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-033